The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia.
The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia.
复制标题
DOI:
10.1097/mph.0b013e3181864a5e
复制
发表时间:
2008-11
期刊:
影响因子:
--
通讯作者:
Krischer JP
中科院分区:
文献类型:
--
作者:
Couluris M;Mayer JL;Freyer DR;Sandler E;Xu P;Krischer JP
Children with cancer frequently have associated cachexia and malnutrition. Failure to thrive affects nearly 40% of oncology patients with advanced or progressive disease. Malnutrition can erode quality of life and adversely impact disease prognosis. Appetite stimulation and increased food intake is one approach to combat cancer-related cachexia. Cyproheptadine hydrochloride (CH), an appetite stimulant, was administered to children with cancer-associated cachexia to prevent further weight loss. All participants started CH and were evaluated for response after four weeks. Efficacy of megestrol acetate (MA) was evaluated in patients who did not respond to CH. Medical evaluation, weight measurements, prealbumin and serum leptin levels were preformed at follow-up visits. Seventy patients were enrolled. Of the 66 evaluable patients, 50 demonstrated a response to CH (average weight gain 2.6kg and mean weight-for-age z-score change of 0.35, p=0.001). Seven of the 16 non-responders received MA. Six patients completed four weeks of MA, 5 responded (average weight gain of 2.5kg). The most commonly reported side effect of CH was drowsiness. One patient on MA developed low cortisol levels and hyperlipidemia. This study demonstrates that CH is a safe and effective way to promote weight gain in children with cancer/treatment-related cachexia.